Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Overview
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing methyl salicylate for dermal use, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for methyl salicylate-containing medicines in RASML follows previously implemented requirements for advisory statements on labels of methyl salicylate-containing listed medicines.
Why we are consulting
The TGA is requesting comments that will help ensure that the proposed advisory statements are appropriate and support the quality use of the medicines and that any label changes that would be required for these medicines are made in the most convenient, efficient and cost-effective way.
Consultation paper
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Providing feedback
We invite you to provide your feedback by clicking 'Make a submission' below and responding to the consultation question (by free text and/or file upload).
Have your say
This consultation will open on 6 Apr 2021. Please come back on or after this date to give us your views.Audiences
- Academics
- Non-government organisations
- State government agencies
- Commonwealth agencies
- Health professionals
- General public
- Community groups
- HPRG (TGA) Staff
- Complementary medicines
- Over-the-counter medicines
Interests
- Non-prescription medicines
Share
Share on Twitter Share on Facebook